The Russian market of anticoagulants has been expanded with European rivaroxan produced by Egis Pharmaceuticals PLC (Hungary). The product from the class of direct oral anticoagulants combines European manufacturing standards and practical benefits for patients. With a convenient one-pill-per-day regime and affordability, this product opens up new possibilities in the prevention of thrombosis, significantly increasing the availability of modern anticoagulation therapy and contributing to improved patient commitment to long-term treatment.

Egis Pharmaceuticals Plc. applied for the prestigious Top Employer Hungary certification for the first time and successfully joined the ranks of companies recognized for their outstanding employer practices on an international level.

New Year´s is a time of miracles, but these miracles are especially important for children who are celebrating the holiday in hospitals. That´s why Egis joined the initiative of the Charity foundation Podari Zhizn to collect New Year´s gifts. Through our inhouse charitable campaign ˝The Tree of Kindness˝ , we were able to become a part of a big movement that turns the dreams of young patients in Moscow´s oncology centers into reality.